{"preliminary_commentary":{"by_channel":{"x_thread":43,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06346392\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CLARITY Gastric 01","nct_id":"NCT06346392","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=clarity-gastric-01-nct06346392. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants in the AZD0901 arm 1 will receive AZD0901 dose level 1 intravenous infusion treatment.","label":"AZD0901 arm 1","type":"EXPERIMENTAL"},{"description":"Participants in the AZD0901 arm 2 will receive AZD0901 dose level 2 intravenous infusion treatment. (Enrolment was closed)","label":"AZD0901 Arm 2","type":"EXPERIMENTAL"},{"description":"Participants in the Investigator's choice arm will receive a regimen of Investigator's choice, including regionally accepted chemotherapies or targeted therapies.","label":"Investigator's choice arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-14","type":"ESTIMATED"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":{"count":594,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AZD0901","otherNames":["Sonesitatug Vedotin"],"type":"DRUG"},{"name":"AZD0901","otherNames":["Sonesitatug Vedotin"],"type":"DRUG"},{"name":"Ramucirumab+ paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"TAS-102","otherNames":[],"type":"DRUG"},{"name":"Apatinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"AstraZeneca","official_title":"A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-05-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) in all randomized participants","timeFrame":"From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years)."},{"measure":"Overall Survival (OS) for 3L+ participants","timeFrame":"From date of first dose/randomisation until the date of death due to any cause (approximately 3 years)."}],"references":[{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"},{"citation":"Xu G, Liu W, Wang Y, Wei X, Liu F, He Y, Zhang L, Song Q, Li Z, Wang C, Xu R, Chen B. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep Med. 2024 Sep 17;5(9):101710. doi: 10.1016/j.xcrm.2024.101710. Epub 2024 Sep 3.","pmid":"39232496","type":"DERIVED"}],"start_date":{"date":"2024-03-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","url":"https://clinicaltrials.gov/study/NCT06346392"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/clarity-gastric-01-nct06346392"}